Jennifer Goldsack is the Chief Executive Officer of the Digital Medicine Society (DiMe). Founded in 2019, DiMe is the first professional organization for experts from all disciplines comprising the diverse field of digital medicine. Together, we drive scientific progress and broad acceptance of digital medicine to enhance public health. DiMe is a 501c3 non-profit organization dedicated to advancing digital medicine to optimize human health. We do this by serving professionals at the intersection of the global healthcare and technology communities, supporting them in developing digital medicine through interdisciplinary collaboration, research, teaching, and the promotion of best practices.

Lindsay Kehoe, M.S., C.G.C., is a senior project manager at the Clinical Trials Transformation Initiative (CTTI), where she manages the development and implementation of CTTI projects. She has convened teams around disease progression modeling, embedding trials into clinical practice, and using digital health technologies to advance novel endpoint acceptance. Along with her colleagues, Ms. Kehoe is accelerating progress toward the CTTI Transforming Trials 2030 Vision. Prior to CTTI, she served as a clinical trial lead and on the IRB at Children’s National Medical Center. She is a certified genetic counselor and has worked for industry in early phase drug development and post marketing surveillance.

Michelle Crouthamel is a recognized industry leader who integrates digital health in pharmaceutical development and collaborates broadly with academics, tech, consortia, and health authorities to create impacts. As the Head of Digital Science at AbbVie, Michelle leads digital strategy and implementation in RCT and RWE. Prior to joining AbbVie, Michelle led many successful R&D programs at Merck and GSK. She is a scientific advisor to many tech companies, an inventor who holds multiple patents, and an author who published extensively in Neuroscience, Oncology, and Digital Health.